HealthQuill Investigational Drug
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid tumours, for $2.5 billion in cash.
Drugs Health Medical

Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.

Read More
GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Drugs Health Medical

GSK to pay Chimagen $300m upfront to develop autoimmune drug 

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

Read More
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Drugs Health Pharma

AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.

Read More
Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%, the latest results of the company's trials reveal.
Drugs Health Pharma

Summit’s lung cancer drug reduces risk of disease progression by 48%

Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%,.

Read More
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated the drug wouldn’t succeed.
Drugs Health Pharma

Merck halts small cell lung cancer immunotherapy drug trial

Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.

Read More
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to the company.
Drugs Health Pharma

Merck’s experimental RSV injection lowers infections in infants 

The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.

Read More
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.
Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

Read More